Tags:

Transcription

SUPPLEMENT5Volume 17 # Number 6 # DECEMBER 2011Editor-in-ChiefIgnatius TS Yu 余德新Senior EditorsPT Cheung 張璧濤CB Chow 周鎮邦Albert KK Chui 徐家強Michael G IrwinEditorsKL Chan 陳廣亮KS Chan 陳健生Henry LY Chan 陳力元David VK Chao 周偉強TW Chiu 趙多和Stanley ST Choi 蔡兆堂LW Chu 朱亮榮WK Hung 熊維嘉TL Kwan 關添樂Alvin KH Kwok 郭坤豪Paul BS Lai 賴寶山Eric CH Lai 賴俊雄Stephen TS Lam 林德深WY Lam 林永賢Patrick CP Lau 劉志斌Arthur CW Lau 劉俊穎Nelson LS Lee 李禮舜Danny WH Lee 李偉雄KY Leung 梁國賢Danny TN Leung 梁子昂Thomas WH Leung 梁慧康WK Leung 梁惠強Kenneth KW Li 李啟煌David TL Liu 劉大立Janice YC Lo 羅懿之Herbert HF Loong 龍浩鋒James KH Luk 陸嘉熙Ronald CW Ma 馬青雲Ada TW Ma 馬天慧Jacobus KF Ng 吳國夫Hextan YS Ngan 顏婉嫦Martin W Pak 白威PC Tam 談寶雛SW Tang 鄧兆華William YM Tang 鄧旭明Clement CY Tham 譚智勇Martin CS Wong 黃至生Kenneth KY Wong 黃格元TW Wong 黃大偉Patrick CY Woo 胡釗逸TK Yau 游子覺2nd Hong Kong Neurological Congress cum24th Annual Scientific Meeting of The Hong Kong NeurologicalSocietyCouncil of The Hong Kong Neurological Society5Organising Committee5List of Speakers6Scientific Programme7SESSIONABSTRACTPAGEFREE PAPER PRESENTATIONS3D Rotational Angiography as a Screening Imaging Testfor Intracranial StentingFlorence SY FanFP 110Intravenous Alteplase for Ischaemic Stroke Patients withBorderline Eligibility in Hong Kong—How Selective ShouldWe Be?Alexander Lau, Edward Wong, Yannie Soo, Deyond Siu,Venus Hui, Edward Shum, Cecilia Leung, Colin Graham,Thomas Leung, Lawrence WongFP 210Subthalamic Deep Brain Stimulation for AdvancedParkinson’s Disease: Efficacy and ComplicationsMovement Disorder Group, Prince of Wales Hospital,The Chinese University of Hong Kong; Anne Chan, JonasHM Yeung, Danny TM Chan, XL Zhu, Edith Wong, KY Lau,Rosanna Wong, Christine Lau, Vincent CT Mok, WayneWS PoonFP 311Guillain-Barré Syndrome: a Retrospective Study of ClinicalProfiles and Outcomes in a Tertiary CentreAnna HY Wong, YF Cheung, WC Fong, KW Fong, HF Chan,YW Ng, LT Chan, YC Chan, WT Lo, M Ismail, HM Chan, P LiFP 411Stroke in Tuberculous MeningitisYP Chu, MK Fong, B Sheng, YH Chan, WT Wong, KK LauFP 512Transient Axonal Glycoprotein-1 (TAG-1) PolymorphismDH 1and Its Correlation with Clinical Features and Prognosis inChronic Inflammatory Demyelinating Polyradiculoneuropathy(CIDP)Shirley YY Pang13DISSERTATION HIGHLIGHTSAdvisors on BiostatisticsWilliam B GogginsEddy KF Lam 林國輝Advisor on Clinical EpidemiologyShelly LA Tse 謝立亞Hong Kong Med J Vol 17 No 6 # Supplement 5 # December 20111

INTERNATIONAL EDITORIALADVISORY BOARDSabaratnam ArulkumaranUnited KingdomRobert AtkinsAustraliaPeter CameronAustraliaJames DickinsonCanadaAdrian DixonUnited KingdomWillard Fee, JrUnited StatesRobert HoffmanUnited StatesSean HughesUnited KingdomArthur KleinmanUnited StatesXiaoping LuoChinaJonathan SametUnited StatesRainer SchmelzeisenGermanyDavid WeatherallUnited KingdomHomer YangCanadaEXECUTIVE EDITORCyrus R KumanaMANAGING EDITORYvonne Kwok 郭佩賢ASSISTANT MANAGING EDITORSWarren Chan 陳俊華Betty Lau 劉薇薇2SESSIONUsefulness of ABCD2 Score in Prediction of 90-day Riskof Stroke in Patients with Transient Ischaemic Attack in aChinese, Non-tertiary Care Community HospitalKK WongABSTRACTDH 2PAGE14Clinical Profile and Prognosis of Patients with MyastheniaGravis in Hong KongEric SW YeungDH 315Factors Associated with the Risk of Thymoma at thePresentation of Myasthenia GravisKY CheungDH 416Predictors of Early Neurological Deterioration During Acute DH 5Phase of Ischaemic Stroke: Experience in Acute Stroke Unitat a Regional Hospital in Hong KongGrace LY Cheung17SYMPOSIUM ON PERIPHERAL NEUROPATHYFocal NeuropathiesWindsor MakS117Guillain-Barré Syndrome: the Immunopathogenesis andRelationship between the Different SubtypesNobuhiro YukiS218Common Pitfalls in the Electrodiagnosis of EntrapmentNeuropathyAlex CP ChowS318Idiopathic Intracranial HypertensionBL ManS419Atypical Optic NeuritisCarmen KM Chan, Andy CO ChengS519Using Eye Movements for Topological Diagnosis of CentralDisordersDavid S ZeeS620SYMPOSIUM ON NEURO-OPHTHALMOLOGYNOVARTIS SYMPOSIUM ON MOVEMENT DISORDERSJOINT SYMPOSIUM WITH THE HONG KONG MOVEMENTDISORDER SOCIETYNew Targets for Treatments of Parkinson’s DiseaseKen KL Yung, John MT Chu, Cathy NP Lui, Olivia TW NgS721Levodopa/carbidopa/entacapone as First-line LevodopaFormulation: Pharmacokinetic ConsiderationsThomas MüllerS821Homocysteine and Entacapone TreatmentThomas MüllerS 1022Deep Brain Stimulation for the Treatment of Parkinson’sDiseaseEugene C LaiS 1122Hong Kong Med J Vol 17 No 6 # Supplement 5 # December 2011

SESSIONABSTRACTPAGEORIENT EUROPHARMA SYMPOSIUM ON EPILEPSYJOINT SYMPOSIUM WITH HONG KONG EPILEPSY SOCIETYPsychogenic Non-epileptic SeizuresDavid G VosslerS 1223Upcoming Antiepileptic Drugs: the United States ExperienceDavid G VosslerS 1323GLAXOSMITHKLINE SYMPOSIUM ON EPILEPSYJOINT SYMPOSIUM WITH HONG KONG EPILEPSY SOCIETYSleep and EpilepsyCarl BazilS 1424Psychiatric Issues in Epileptic DisordersJoyce LamS 1525Basic Neurogenetics: What Clinical Neurologists Need to Know S 16KY Mok25Molecular Neurogenetics: Tools and MethodshLiz YP YuenS 1726Advanced Neurogenetics: Frontiers in ResearchKY MokS 1826Current Approach for Chronic Migraine ManagementSJ WangS 1927Updated Guidelines for Treatment of Neuropathic PainPP ChenS 2028Trigeminal Autonomic CephalalgiasTH TsoiS 2129S 2230SYMPOSIUM ON NEUROGENETICSALLERGAN SYMPOSIUM ON HEADACHE & PAINBAYER LUNCH SYMPOSIUMAnticoagulation for Prevention of Stroke in Patients withAtrial FibrillationJaseong KooSYMPOSIUM ON MOYAMOYA DISEASEJOINT SYMPOSIUM WITH THE HONG KONG STROKE SOCIETYSurgical Outcomes from Revascularisation Surgery forMoyamoya Disease: Experience in Tuen Mun Hospital,Hong KongKF Fok, WL Poon, YC Wong, Florence Kwok, Dawson FongS 2331Surgical Management of Moyamoya DiseaseKC WangS 2432SYMPOSIUM ON ISCHAEMIC STROKEJOINT SYMPOSIUM WITH THE HONG KONG STROKE SOCIETYMechanical Thrombectomy in Ischaemic Stroke: a Look atthe ToolboxFerdinand HuiS 2533Medical Management of Intracranial StenosisKazunori ToyodaS 2634Hong Kong Med J Vol 17 No 6 # Supplement 5 # December 20113

SESSIONABSTRACTPAGEPOSTERSOff-label Use of Rituximab in Refractory NeurologicalAutoimmune Diseases—Experiences of a Regional TeachingHospital in Hong KongVincent HL Ip, Alexander YL Lau, Anne YY Chan, Lisa WC Au,Florence SY Fan, Nick NC Ng, Edward HC Wong, Yannie OYSoo, Vincent CT Mok, Thomas WH Leung, Lawrence KS WongP135Cisplatin Neuropathy: a Prospective Study on Chinese Patients P 2KF Ko, WY Lau, WK Cheng, MC Kwan, LK Yip, KP Yiu35A Lady with Autoimmune Lymphocytic HypophysitisPresenting with Right 3rd, 4th and 6th PalsiesSH LiP336Long-term Outcome of Stroke Thrombolysis in Hong KongChinese PatientsEdward WongP437Do Cerebral Microbleeds Increase Intracranial HaemorrhageRisk in Hong Kong Stroke Patients Receiving ThrombolyticTherapy?Edward Wong, Alexander Lau, Yannie Soo, Deyond Siu,Jill Abrigo, Tom Cheung, Venus Hui, Lawrence WongP537Intravenous Thrombolysis Versus Intra-arterial RecanalisationTherapy for Acute Ischaemic Stroke Due to Large ArteryOcclusion—Comparison of Outcomes from a Hong KongHospitalEdward Wong, Simon Yu, Alexander Lau, Joyce Hui, DeyondSiu, Colin Graham, Cecilia Leung, Venus Hui, Lawrence Wong,Thomas LeungP638The Efficacy of Deep Brain Stimulation for AdvancedParkinson’s DiseaseYF Cheung, HF Chan, TL Poon, PMP Choi, WS Chan, FCCheung, HM Chan, P LiP738A Case with Atypical Neuroleptic Malignant SyndromeOC Lau, BH Fung, PW Ng, CH Lo, CK Chan, KY CheungP839Headache Associated with Chest Pain and ECGAbnormalities: What Can It Be?Raymond CK Chan, CH Lo, PW NgP939AUTHOR INDEX4Hong Kong Med J Vol 17 No 6 # Supplement 5 # December 201140

Council of The Hong Kong Neurological SocietyPresidentVice-PresidentHon SecretaryHon TreasurerCouncil MembersAd Hoc MemberPast PresidentHon Legal AdvisorHon AuditorDr Leonard Sheung-wai Li 李常威醫生Dr Jonas Hon-ming Yeung 楊漢明醫生Dr Kwok-kwong Lau 劉國光醫生Dr Wing-chi Fong 方榮志醫生Dr Eric Lok-yiu Chan 陳樂耀醫生Dr Nelson Yuk-fai Cheung 張煜暉醫生Dr Gardian Chung-yan Fong 方頌恩醫生Dr Sonny Fong-kwong Hon 韓方光醫生Dr Kwok-fai Hui 許國輝醫生Dr Thomas Wai-hong Leung 梁慧康醫生Dr Colin Hiu-tung Lui 呂曉東醫生Prof Vincent Chung-tong Mok 莫仲棠教授Dr Bun Sheng 盛斌醫生Dr Kin-lun Tsang 曾建倫醫生Dr Winnie Wing-yin Wong 黃詠妍醫生Dr Tak-hong Tsoi 蔡德康醫生Dr Ping-wing Ng 吳炳榮醫生Mr Tsang-hoi Koo 顧增海律師Mr Eric Li 李家祥先生Organising Committee of the 2nd Hong Kong Neurological Congress cum 24th AnnualScientific Meeting of The Hong Kong Neurological SocietyChairmenScientific CommitteePublication CommitteeWebsiteDr Jonas Hon-ming Yeung 楊漢明醫生Dr Leonard Sheung-wai Li 李常威醫生 (Co-Chair)Dr Wing-chi Fong 方榮志醫生Dr Gardian Chung-yan Fong 方頌恩醫生Dr Sonny Fong-kwong Hon 韓方光醫生Dr Kwok-fai Hui 許國輝醫生Dr Thomas Wai-hong Leung 梁慧康醫生Dr Colin Hiu-tung Lui 呂曉東醫生Prof Vincent Chung-tong Mok 莫仲棠教授Dr Winnie Wing-yin Wong 黃詠妍醫生Dr Eric Lok-yiu Chan 陳樂耀醫生Dr Nelson Yuk-fai Cheung 張煜暉醫生Dr Kwok-kwong Lau 劉國光醫生Dr Bun Sheng 盛斌醫生Dr Kin-lun Tsang 曾建倫醫生Hong Kong Med J Vol 17 No 6 # Supplement 5 # December 20115

List of SpeakersNameProf Carl BazilDr Carmen Kar-mun ChanDr Phoon-ping ChenDr Andy Chi-on ChengDr Alex Chi-ping ChowDr Kam-fuk FokDr Ferdinand HuiProf Jaseong KooProf Eugene C LaiDr Joyce LamDr Windsor MakDr Bik-ling ManDr Kin-ying MokProf Thomas MüllerDr Kazunori ToyodaDr Tak-hong TsoiProf David G VosslerProf Kyu-chang WangProf Shuu-jiun WangProf Ruey-meei Robin WuDr Liz Yuet-ping YuenProf Nobuhiro YukiProf Ken KL YungDr David S Zee6AffiliationCollege of Physicians and Surgeons at ColumbiaUniversity, United StatesHong Kong Eye Hospital, Hong Kong SARAlice Ho Miu Ling Nethersole Hospital / North DistrictHospital, Hong Kong SARHong Kong Eye Hospital, Hong Kong SARHong Kong Sanatorium & Hospital, Hong Kong SARTuen Mun Hospital, Hong Kong SARCleveland Clinic Foundation, United StatesCatholic University of Korea, KoreaThe Methodist Neurological Institute, Houston, Texas,United StatesThe Chinese University of Hong Kong, Hong Kong SARQueen Mary Hospital, Hong Kong SARTuen Mun Hospital, Hong Kong SARUCL Institute of Neurology, United KingdomSt Joseph Hospital Berlin-Weissensee, GermanyNational Cerebral and Cardiovascular Center, Osaka,JapanPamela Youde Nethersole Eastern Hospital, Hong KongSARUniversity of Washington, Seattle, United StatesSeoul National University Hospital, KoreaNational Yang-Ming University School of Medicine,TaiwanNational Taiwan University, TaiwanThe Chinese University of Hong Kong, Hong Kong SARNational University of Singapore, SingaporeHong Kong Baptist University, Hong Kong SARJohns Hopkins School of Medicine, United StatesHong Kong Med J Vol 17 No 6 # Supplement 5 # December 2011

SCIENTIFIC PROGRAMMEVenue: Grand Ballroom, Level LL1, Kowloon Shangri-La Hotel28 October 2011, Friday09:00 – 09:3009:30 – 11:00Registration11:00 – 11:2011:20 – 12:30Coffee BreakDISSERTATION HIGHLIGHTS12:30 – 13:3013:30 – 15:00LunchSYMPOSIUM ON PERIPHERAL NEUROPATHYFunction RoomFREE PAPER PRESENTATIONChairpersons: Thomas Leung, Winnie WongPosterPRESENTATIONChairpersons: Thomas Leung, Winnie WongChairpersons: Bun Sheng, Leonard LiFocal NeuropathiesWindsor MakGuillain-Barré Syndrome: the Immunopathogenesis andRelationship between the Different SubtypesNobuhiro YukiCommon Pitfalls in the Electrodiagnosis of EntrapmentNeuropathyAlex CP Chow15:00 – 15:2015:20 – 16:45Coffee BreakSYMPOSIUM ON NEURO-OPHTHALMOLOGYChairpersons: SH Ng, Nelson YF CheungIdiopathic Intracranial HypertensionBL ManAtypical Optic NeuritisCarmen KM Chan, Andy CO ChengUsing Eye Movements for Topological Diagnosis ofCentral DisordersDavid S ZeeHong Kong Med J Vol 17 No 6 # Supplement 5 # December 20117

29 October 2011, Saturday09:00 – 09:3009:30 – 09:40Registration09:40 – 10:45NOVARTIS SYMPOSIUM ON MOVEMENT DISORDERSJOINT SYMPOSIUM WITH THE HONG KONGMOVEMENT DISORDER SOCIETYFunction RoomOPENING CEREMONYWelcome Remarks: Dr Leonard SW LiPresident of the Hong Kong Neurological SocietyGuest of Honour: Mr Richard MF Yuen, JPPermanent Secretary for Food and Health (Health)Chairpersons: Mandy Au Yeung, KL TsangNew Targets for Treatments of Parkinson’s DiseaseKen KL YungLevodopa/carbidopa/entacapone as First-line LevodopaFormulation: Pharmacokinetic ConsiderationsThomas Müller10:45 – 11:0011:00 – 12:35Coffee BreakNOVARTIS SYMPOSIUM ON MOVEMENT DISORDERSJOINT SYMPOSIUM WITH THE HONG KONGMOVEMENT DISORDER SOCIETYChairpersons: Vincent Mok, XL ZhuRoutine Genetic Screening for Young Onset / FamilialParkinson’s Disease in Chinese—Are We Ready?Ruey-Meei Robin WuHomocysteine and Entacapone TreatmentThomas MüllerDeep Brain Stimulation for the Treatment of Parkinson’sDiseaseEugene C Lai12:35 – 13:3013:30 – 15:00LunchORIENT EUROPHARMA SYMPOSIUM ON EPILEPSYJOINT SYMPOSIUM WITH HONG KONG EPILEPSYSOCIETYChairpersons: Colin Lui, Ada YungPsychogenic Non-epileptic SeizuresDavid G VosslerUpcoming Antiepileptic Drugs: the United StatesExperienceDavid G Vossler15:00 – 15:2015:20 – 17:00Coffee BreakGLAXOSMITHKLINE SYMPOSIUM ON EPILEPSYJOINT SYMPOSIUM WITH HONG KONG EPILEPSYSOCIETYChairpersons: Eric Chan, Howan LeungSleep and EpilepsyCarl BazilPsychiatric Issues in Epileptic DisordersJoyce Lam8Hong Kong Med J Vol 17 No 6 # Supplement 5 # December 2011PosterPRESENTATION

30 October 2011, Sunday09:00 – 09:3009:30 – 11:05RegistrationSYMPOSIUM ON NEUROGENETICSChairpersons: Jonas Yeung, YL YuFunction RoomPosterPRESENTATIONBasic Neurogenetics: What Clinical Neurologists Needto KnowKY MokMolecular Neurogenetics: Tools and MethodsLiz YP YuenAdvanced Neurogenetics: Frontiers in ResearchKY Mok11:05 – 11:2011:20 – 12:35Coffee BreakALLERGAN SYMPOSIUM ON HEADACHE & PAINChairpersons: YW Chan, Edmund WooCurrent Approach for Chronic Migraine ManagementSJ WangUpdated Guidelines for Treatment of Neuropathic PainPP ChenTrigeminal Autonomic CephalalgiasTH Tsoi12:35 – 14:00BAYER LUNCH SYMPOSIUMChairpersons: Patrick Li, PW NgAnticoagulation for Prevention of Stroke in Patientswith Atrial FibrillationJaseong Koo14:00 – 15:05SYMPOSIUM ON MOYAMOYA DISEASEJOINT SYMPOSIUM WITH THE HONG KONGSTROKE SOCIETYChairpersons: Dawson Fong, WC FongSurgical Outcomes from Revascularisation Surgery forMoyamoya Disease: Experience in Tuen Mun Hospital,Hong KongKF FokSurgical Management of Moyamoya DiseasesKC Wang15:05 – 15:2015:20 – 17:00Coffee BreakSYMPOSIUM ON ISCHAEMIC STROKEJOINT SYMPOSIUM WITH THE HONG KONGSTROKE SOCIETYChairpersons: Raymand Lee, Sonny HonMechanical Thrombectomy in Ischemic Stroke: a Lookat the ToolboxFerdinand HuiMedical Management of Intracranial StenosisKazunori Toyoda17:00Closing Remarks and Presentation of Awards toBest Free Paper, Best Poster and Best DissertationPresentationsHong Kong Med J Vol 17 No 6 # Supplement 5 # December 20119

3D Rotational Angiography as a Screening Imaging Test for IntracranialStentingFP 1Florence SY FanDepartment of Medicine and Therapeutics, Prince of Wales Hospital, Hong Kong SARBackground: 3D rotational angiography (3DRA) is a new technique in delineating fine details of intracranialvasculature. We investigated the role of 3DRA in selecting patients for intracranial self-expandablestenting.Methods: Patients who had strokes referrable to a high-grade symptomatic stenosis were recruited andunderwent screening for intracranial stenting by a conventional digital subtraction angiography (DSA)and a 3DRA. Both imaging tests were performed by a biplane angiographic equipment (Allura XperFD 20/20, Philips Medical Systems, Netherland). DSA consisted of anteroposterior, lateral and bilateraloblique views of the target artery with 10 mL of iopamiro 300 in each injection from a 4F H1 catheterpositioned at internal carotid artery or vertebral artery ostium. By the same catheter and contrast, 3DRAwas obtained by a rotating arm centred at the target lesion, comprising 120 images gathered over a scantime of 4 seconds. A radiologist blind to the patient’s clinical information compared the anatomy of thelesion and its immediate vicinity as revealed by the two imaging methods. The degree of stenosis wasmeasured by WASID technique. Lesion characteristics which might alter the decision of endovasculartreatment were recorded.Results: Paired DSA and 3DRA were obtained in 169 patients. The two methods were comparable inthe measurement of the stenosis severity. However, among the four patients who had fenestrationsmimicking or adjacent to the stenosis (middle cerebral artery 3; basilar arterty 1), three were onlyevident in 3DRA but not in convention DSA. In another three patients, angioplasty/stenting was precludedbased on 3DRA which showed an adjacent perforator or branch with a highly stenosed ostium.Conclusions: 3DRA may compare favourably with conventional DSA in depicting minute details ofintracranial vascular anatomy, and is potentially useful in preoperative evaluation of intracranialangioplasty.Intravenous Alteplase for Ischaemic Stroke Patients with Borderline Eligibilityin Hong Kong—How Selective Should We Be?FP 2Alexander Lau1, Edward Wong1, Yannie Soo1, Deyond Siu2, Venus Hui1, Edward Shum1, Cecilia Leung1, Colin Graham3, ThomasLeung1, Lawrence Wong11Department of Medicine and Therapeutics, Prince of Wales Hospital, Hong Kong SAR2Department of Imaging and Interventional Radiology, Prince of Wales Hospital, Hong Kong SAR3Department of Accident and Emergency Medicine, Prince of Wales Hospital, Hong Kong SARBackground: Variance exists in selecting patients for stroke thrombolysis. Unlike US labelling, intravenousalteplase (IVTPA) is not recommended for age 80 years and NIHSS 25 by European guideline. Besides,both exclude patients 80 years or with a history of diabetes and stroke for the 3-4.5 hours window. Wecompared the outcomes of patients who received IVTPA outside these guidelines to those who complied,and to a control group.Methods: Consecutive patients received IVTPA 4.5 hours between January 2007 and June 2011 at ourcentre were reviewed. Patients compliant to both guidelines were compared to those who did not. Theywere further compared to a control group with the same borderline eligibility but were not given IVTPAdue to non-office hours admission between October 2008 and May 2011. Outcome measures were3-month modified Rankin Scale (mRS) 2 and mortality, and symptomatic intracranial haemorrhage (SICH)according to ECASS (European Cooperative Acute Stroke Study).Results: Fifty-four patients received IVTPA. Thirty-three were compliant to both guidelines and 21 werenon-compliant. For non-compliant group (mean age 81.6 8.2, NIHSS 18.6 8.2), 16 were 80 years, 5had NIHSS 25, and 2 thrombolysed between 3-4.5 hours had a history of both diabetes and stroke or 80 years. For comparison, 22 non-thrombolysed controls (mean age 77.0 10.9, NIHSS 19.1 10.1) wereidentified. Twenty (61%) of the compliant group versus 4 (19%) of the non-compliant and none of controlgroups attained 3-month mRS 2 (non-compliant vs control, P 0.05). Three-month mortality rates were 3%,43% and 27% for compliant, non-compliant, and control groups respectively (non-compliant vs control,P 0.35). SICH occurred in one, two, and one patients of compliant, non-compliant and control groups,respectively.Conclusions: The outcomes of patients given IVTPA outside both US and European guidelines had pooreroutcomes compared to those who fulfilled. Still, those who were not given IVTPA fared even poorer. Furtherprospective randomised trials are needed to substantiate the use of IVTPA in borderline eligible patients.10Hong Kong Med J Vol 17 No 6 # Supplement 5 # December 2011

Subthalamic Deep Brain Stimulation for Advanced Parkinson’s Disease:Efficacy and ComplicationsFP 3Movement Disorder Group, Prince of Wales Hospital, The Chinese University of Hong Kong; Anne Chan1, Jonas HM Yeung1,Danny TM Chan2, XL Zhu2, Edith Wong2, KY Lau2, Rosanna Wong3, Christine Lau1, Vincent CT Mok1, Wayne WS Poon21Division of Neurology, Department of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong,Hong Kong SAR2Division of Neurosurgery, Department of Surgery, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong SAR3Department of Occupational Therapy, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong SARBackground: Deep brain stimulation (DBS) of subthalamic nucleus (STN) was first performed in HongKong since 1998 at our centre for patients with advanced Parkinson’s disease (PD). We hereby report theefficacy and complications of STN DBS for advanced PD.Methods: All PD patients who received STN DBS from September 1998 to January 2010 were included inthe present analyses. We compared the Unified Parkinson’s Disease Rating Scale (UPDRS) before and atleast 2 months after the operation. Peri-operative complications were noted.Results: A total of 41 PD patients (mean age, 54 years; 21 males) received bilateral STN DBS. The medianfollow-up duration was 12 months (range, 2-77 months). There was a significant overall improvement (31%;P 0.0001) in UPDRS in part III (motor performance) postoperatively at “on stimulation and off medicationcondition” compared with preoperatively at “off medication condition”. There was also a significantimprovement (32%, P 0.0001) in UPDRS part II (functional level) score. Peri-operative complicationsincluded lead fracture (n 1), and lead migration (n 1). There was no perioperative mortality.Conclusions: Our efficacy and safety results were comparable to overseas centres. Overall, STN DBS is aneffective and safe treatment for advanced PD.Guillain-Barré Syndrome: a Retrospective Study of Clinical Profiles andOutcomes in a Tertiary CentreFP 4Anna HY Wong, YF Cheung, WC Fong, KW Fong, HF Chan, YW Ng, LT Chan, YC Chan, WT Lo, M Ismail, HM Chan, P LiDepartment of Medicine, Queen Elizabeth Hospital, Hong Kong SARBackground: Guillain-Barré Syndrome (GBS) is an acute peripheral neuropathy which is potentially fataland debilitating. Effective treatment is available. Local data are scarce. In this study, we reviewed theclinical profiles and outcomes of GBS managed in a tertiary centre in Hong Kong.Methods: A retrospective study was performed on GBS patients who met the Asbury and Cornblath(1990) diagnostic criteria and were admitted between July 2001 and December 2010 to the Department ofMedicine, Queen Elizabeth Hospital. Data were analysed by PASW Statistics 18 software.Results: We found 65 GBS patients within the study period; 44 (68%) were male. The mean age of onsetwas 61 (standard deviation, 15.7) years; 94% were Chinese. The number of patients diagnosed per yearranged from 3 to 13. Symptoms suggestive of antecedent upper respiratory tract infections (48%) andthe gastrointestrinal tract infections (11%) were recorded respectively. Twelve per cent of patients had ahistory of recent vaccination in the past 1 to 3 weeks. Presenting features included limb weakness (94%),facial weakness (10%), numbness (63%), visual symptoms (14%), bulbar symptoms (24%), hyporeflexia/areflexia (78%), ataxia (22%) and dysautonomia (27%). Similar to Caucasian series, acute inflammatorydemyelinating polyradiculoneuropathy (AIDP) was the commonest subtype (57%), followed by axonalsubtypes (AMAN or AMSAN, 21%), Fisher’s syndrome (12%) and Bickerstaff brainstem encephalitis (2%).Around one-third received intensive care unit (ICU) care and one-fourth had respiratory failure requiringmechanical ventilation. Seventeen per cent of patients had temporary tracheostomy performed. For theseselected populations, the mean length of ICU stay was 14 days (95% confidence interval [CI], 8.5-19.6) andthe mean length of mechanical ventilation was 25.5 days (95% CI, 14.4-36.7). At 6 months, 84% of patientssurvived and 66% remained independent in activities of daily living (ADL), as measured by the GlasgowOutcome Scale. Using a multivariate logistic regression model with age, sex, antecedent infection/vaccination, bulbar presentation and disease subtype as covariates, age was the only prognostic factorthat significantly determined the 6-month independency in ADL but not survival.Conclusions: In our cohort, GBS carried significant morbidity and mortality. The only significant predictorwas age in our model. Larger, multicentre studies are warranted for better delineation of clinicalpredictors of adverse outcomes.Hong Kong Med J Vol 17 No 6 # Supplement 5 # December 201111

Stroke in Tuberculous MeningitisFP 5YP Chu, MK Fong, B Sheng, YH Chan, WT Wong, KK LauDepartment of Medicine, Princess Margaret Hospital, Hong Kong SARBackground: The objective of this study was to identify the predictors of stroke in patients withtuberculous meningitis (TBM) and their prognostic implications.Methods: All patients with TBM in Princess Margaret Hospital from 2000 to 2010 were included in thestudy. Of the 34 patients with TBM, 16 patients developed stroke. Potential predictors of stroke includingco-morbidities and biochemical findings were studied. Radiological examinations including computedtomography or magnetic resonance imaging brain were also studied. The neurological outcomemeasured was mortality rate and Modified Rankin Score at 6 months (0-3 vs 4-6).Results: Patients with stroke were older (55.4 15.2 vs 45.9 16.6; P 0.09) and had lower cerebrospinal fluid(CSF)–to–serum glucose ratio (0.24 0.14 vs 0.33 0.14; P 0.09). There were less HIV patients in those withstroke (6.3% vs 22.2%; P 0.19). Most of the infarcts in TBM were multiple (87.5%), bilateral (62.5%), andlocated in basal ganglion (31.3%) and subcortical white matter (50%). Patients with stroke had a highermortality rate (31.2% vs 11.15%; odds ratio [OR] 3.64; P 0.147) and more adverse neurological outcomeat 6 months (56.2% vs 29.4%; OR 3.09; P 0.119). High CSF total protein (2.59 1.3 vs 1.57 0.53; P 0.0096)and older age (64 13.2 vs 44.4 14.5; P 0.014) were associated with adverse neurological outcome at 6months in TBM patients with stroke.Conclusion: Stroke is common in patients with TBM leading to a higher mortality and worse neurologicaloutcome.12Hong Kong Med J Vol 17 No 6 # Supplement 5 # December 2011

Transient Axonal Glycoprotein-1 (TAG-1) Polymorphism and Its Correlationwith Clinical Features and Prognosis in Chronic Inflammatory DemyelinatingPolyradiculoneuropathy (CIDP)DH 1Shirley YY PangDepartment of Medicine, Queen Mary Hospital, Hong Kong SARBackground: Chronic inflammatory demyelinating polyradiculopathy (CIDP) is a heterogeneous groupof acquired disorders characterised by peripheral nerve demyelination. Previous studies have showna good response to immunotherapy but a significant proportion of patients continue to requiremaintenance therapy. A recent study identified a potential genetic marker for responsiveness tointravenous immunoglobulin (IVIG). In this study, CIDP patients were examined to look for associationbetween clinical, electrophysiologic, genetic factors and treatment response as well as risk of treatmentdependence.Methods: Case records of 32 CIDP Chinese patients diagnosed between January 1995 and March2010 at the three Neurology centres on Hong Kong Island (namely, Queen Mary Hospital, PamelaYoude Nethersole Eastern Hospital, and Ruttonjee Hospital) were reviewed to examine their clinicalfeatures, electrophysiologic parameters on presentation, disease course and outcome. Blood sampleswere available from 22 patients and 147 controls. DNA was extracted from peripheral leucocytes andthe transient axonal glycoprotein 1 (TAG-1) genotype for the previously reported single nucleotidepolymorphism (SNP) was determined using the Sequenom MassARRAY system.Results: The overall response rate to immunotherapy with prednisolone, IVIG or plasma exchange (PE)was 80% with no difference detected among the three therapies. Clinical features such as age of onset,duration of symptoms, presence of diabetes mellitus (DM), presence of sensory symptoms and modifiedRankin score (mRS) on presentation did not predict treatment responsiveness. Electrophysiologicparameters on the initial nerve conduction study were also not associated with treatment response. Fiftyeight percent of our patients were dependent on maintenance therapy after a mean follow-up periodof 5.8 years. Clinical features such as age of onset, duration of symptoms and presence of DM were notpredictive of treatment dependence. Patients with more prolonged distal motor latency (DML) in theupper limbs had a higher risk of treatment dependence (P 0.03, OR 1.03). Patients with a higher meanmotor nerve conduction velocity (NCV) in the upper limbs showed a trend of lower risk of treatmentdependence but this did not reach statistical significance. TAG-1 genotypes in 147 healthy controls andin 22 CIDP patients with regard to the SNP designated by rs2275697 were determined and no significantdifference in allele frequency was detected. Furthermore, among CIDP patients, there was no associationbetween TAG-1 genotype and age of onset, presence of DM, mode of onset and disease course. However,those who were homozygous for G had significantly more prolonged DML. Those with the G allelepresent (patients who were either homozygous for G or heterozygous with G/A) had significantly lowercompound muscle action potential (CMAP) amplitude in the upper limbs and more prolonged DML inthe lower limbs than those homozygous for A.Conclusions: The overall treatment response rate in CIDP is high and even patients with advanced age,unfavourable electrophysiologic features and severe disability can improve with treatment. However, asignificant proportion will require long-term maintenance therapy to prevent relapses. Patients whoseinitial nerve conduction study showed more prolonged DML in the upper limbs were at increasedrisk of being treatment dependent. The TAG-1 G allele was found to be associated with the severity ofdemyelination on the initial nerve conduction study in CIDP patients, which suggests a role of TAG-1 inthe pathogenesis of demyelination.Hong Kong Med J Vol 17 No 6 # Supplement 5 # December 201113

Usefulness of ABCD2 Score in Prediction of 90-day Risk of Stroke in Patientswith Transient Ischaemic Attack in a Chinese, Non-tertiary Care CommunityHospi

Edward Wong, Simon Yu, Alexander Lau, Joyce Hui, Deyond Siu, Colin Graham, Cecilia Leung, Venus Hui, Lawrence Wong, Thomas Leung The Efficacy of Deep Brain Stimulation for Advanced P 7 38 Parkinson's Disease YF Cheung, HF Chan, TL Poon, PMP Choi, WS Chan, FC Cheung, HM Chan, P Li A Case with Atypical Neuroleptic Malignant Syndrome P 8 39